BMC Cancer

Abstract Background Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative option for patients with hematologic malignancies, but the limited availability of HLA-matched sibling donors necessitates alternative graft sources. Haploidentical donors (HIDs) and double-unit umbilical cord blood (DUCB) are two widely used alternatives, yet direct comparisons of their clinical outcomes …

Abstract Background Histological transformation represents an important mechanism of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in EGFR-mutant lung cancer; however, its incidence, timing, and post-transformation outcomes remain incompletely characterized. Methods We conducted a systematic review and meta-analysis in accordance with PRISMA guidel…

Abstract Background CDK4/6 inhibitors combined with endocrine therapy constitute the global first-line standard of care for HR + /HER2 − advanced breast cancer (ABC), yet no head-to-head trials comparing different CDK4/6 inhibitors have been conducted, and real-world comparative data in Chinese patients is currently unavailable. Methods We conducted a multicenter retrospective study of 341 Chines…

As a novel inflammatory-nutritional biomarker, the C-reactive protein–albumin–lymphocyte (CALLY) index has demonstrated significant prognostic value in several cancer types. However, its predictive significance for patients with locally advanced non-small cell lung cancer (LA-NSCLC) treated with thoracic radiotherapy (RT) remains elusive. This study aimed to investigate the relationship between t…

Recurrence risk stratification system-guided radioiodine (131I) therapy of differentiated thyroid cancer (DTC) has fallen into dilemma due to its poor feasibility and insufficient justification. Subjects referred for 131I therapy were consecutively labeled with no evidence of disease, unexplained hyperthyroglobulinemia, or known disease based on stimulated serum thyroglobulin, radioiodine uptake,…